Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
81.20
-4.40 (-5.14%)
At close: Mar 27, 2026

TPE:6919 Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-351.92-588.83-488.46-286.16-224.29
Depreciation & Amortization
30.6629.5127.8725.3423.28
Loss (Gain) From Sale of Assets
---0.11-
Stock-Based Compensation
122.165.0522.9819.7174.76
Other Operating Activities
-187.28-6.69-0.35-0.36-3.27
Change in Accounts Receivable
-1.312.71-4.77-3.12-
Change in Inventory
-0.02-1.841.78-2.762.48
Change in Accounts Payable
0.29-0.73-0.832.21-0.41
Change in Unearned Revenue
-2.542.59-3.474.5-
Change in Other Net Operating Assets
-35.88-24.0821.32-2.2216.77
Operating Cash Flow
-425.9-522.31-423.94-242.76-110.7
Capital Expenditures
-16.53-10-8.6-14.16-14.9
Sale of Property, Plant & Equipment
---0-
Sale (Purchase) of Intangibles
-0.61-1.09-1.09--
Investment in Securities
-5,603-2,478166.78-456.18-
Other Investing Activities
-4.61-0.01-0.2-
Investing Cash Flow
-5,624-2,489157.09-470.54-14.9
Long-Term Debt Repaid
-8.88-8.58-8.22-12.6-93.98
Total Debt Repaid
-8.88-8.58-8.22-12.6-93.98
Net Debt Issued (Repaid)
-8.88-8.58-8.22-12.6-93.98
Issuance of Common Stock
44.296,4993,042784.32720.88
Repurchase of Common Stock
-154.52----0.09
Financing Cash Flow
-119.116,4913,034771.72626.81
Foreign Exchange Rate Adjustments
52.24-0.110.321.730.14
Net Cash Flow
-6,1173,4792,76760.15501.35
Free Cash Flow
-442.43-532.31-432.54-256.93-125.6
Free Cash Flow Margin
-1163.16%-1197.97%-1111.01%-2004.12%-1017.90%
Free Cash Flow Per Share
-0.29-0.37-0.35-0.22-0.14
Cash Interest Paid
0.160.330.50.676.18
Cash Income Tax Paid
----0.03
Levered Free Cash Flow
-401.63-391.26-266.4-171.06-74
Unlevered Free Cash Flow
-401.53-391.05-266.09-170.65-72.19
Change in Working Capital
-39.46-21.3514.03-1.418.84
Source: S&P Global Market Intelligence. Standard template. Financial Sources.